VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.05.003
{"title":"Decálogo de buenas prácticas en comunicación sobre vacunas entre pacientes inmunodeprimidos y profesionales sanitarios","authors":"","doi":"10.1016/j.vacun.2024.05.003","DOIUrl":"10.1016/j.vacun.2024.05.003","url":null,"abstract":"<div><p>Communication between health professionals and patients remains a challenge from the point of view of health education and health care. Training in patient-professional communication techniques and improving the communication skills of healthcare professionals is of particular interest. This document aims to share with the healthcare professional community the “Decalogue of good practices in vaccine communication between immunocompromised patients and healthcare professionals”. A QR code is included at the end of the document where the Decalogue can be downloaded for its use and distribution.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2023.10.003
{"title":"Incidence of neurological complication symptoms post-mRNA vaccination among the urban population of Makkah Province of Kingdom of Saudi Arabia","authors":"","doi":"10.1016/j.vacun.2023.10.003","DOIUrl":"10.1016/j.vacun.2023.10.003","url":null,"abstract":"<div><h3>Objective</h3><p><span><span>This research aimed to assess the incidence of neurological complication </span>symptoms<span> among residents of the Makkah province in Saudi Arabia following the rapid approval and administration of </span></span>mRNA<span> vaccines. Given the differences in demographic factors such as age, race, medical history<span>, and lifestyle among individuals, close monitoring of vaccine-related side effects becomes crucial, especially in mass vaccination campaigns.</span></span></p></div><div><h3>Method</h3><p><span>A cross-sectional online survey study was conducted in both English and Arabic languages<span>, with a sample size determined using the Raosoft sample size calculator statistical analyzer. The study aimed for a 95% confidence level, a 5% margin of error, and a response distribution of 50%. </span></span>Descriptive statistics were employed using Statistical Package for Social Sciences version 22.0. The Shapiro–Wilk test was utilized to assess data normality, and the statistical significance of the data was determined using Pearson's Chi-Squared test and the Kruskal–Wallis test.</p></div><div><h3>Result</h3><p>The study included 846 volunteers aged 18 and above, all of whom had received mRNA vaccine in the Makkah region. Data were systematically tabulated and categorized for descriptive analysis. The study found <em>P</em>-values less than .05, and the summarized <em>P</em>-values were presented. The majority of participants (73%) were from the Taif area (32%) within the Makkah region.</p></div><div><h3>Conclusion</h3><p>This study sheds light on the challenges faced by the population of the Makkah region in Saudi Arabia following mRNA vaccinations. Although some complications were reported post-vaccination, it is noteworthy that these challenges were effectively managed by the medical authorities.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135564424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.06.002
{"title":"Importancia de las agencias reguladoras nacionales y los laboratorios nacionales de control ante la pandemia de COVID-19: experiencia de la Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS)","authors":"","doi":"10.1016/j.vacun.2024.06.002","DOIUrl":"10.1016/j.vacun.2024.06.002","url":null,"abstract":"<div><p>COVID-19 pandemic has challenged the National Regulatory Agencies (NRA). One of these challenges is the transfer and validation of new vaccine methodologies so that they are safe, quality and effective in protecting the population. In this article, we review the process that the Mexican NRA followed for the Vaxzevria™ and Convidecia® vaccines; where communication between manufacturers and NRA allowed the methodological transfer and validation to be carried out before the first batch for application was ready in compliance with WHO guidelines. In this way, the importance of the relationship that must exist between manufacturers and NRAs is manifested to provide an immediate response and provide the population with a means of protection in the event of a public health emergency.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.05.001
{"title":"Anti-SARS-CoV-2 Omicron BA.5 RBD antibody titers generated by the protein subunit vaccine Abdala in breast milk","authors":"","doi":"10.1016/j.vacun.2024.05.001","DOIUrl":"10.1016/j.vacun.2024.05.001","url":null,"abstract":"<div><h3>Objective</h3><p>In this work, we investigate the presence of antibodies against OmicronBA.5 RBD in breast milk from puerperal women, vaccinated during pregnancy with the protein subunit vaccine Abdala, based on the Wuhan-Hu-1 RBD.</p></div><div><h3>Materials and methods</h3><p>Breast milk samples were collected between September 30 and November 25, 2021, from 2 groups of participants: 5- and 9-weeks after the third dose of the vaccine. Antibody titers against OmicronBA.5 RBD and Wuhan-Hu-1 RBD were evaluated simultaneously by a homemade ELISA<em>.</em> The relationship of antibody titers with the parity at the beginning of vaccination and with the participants health status was assessed.</p></div><div><h3>Results</h3><p>Binding of OmicronBA.5 RBD, such as Wuhan-Hu-1, to IgA and IgG antibodies was detected in all breast milk samples, although the anti-RBD-Wuhan-Hu-1 titers were higher. The immune response to OmicronBA.5 could be related to the glycosylation of the Abdala RBD, expressed in <em>Pichia pastoris</em>, which contributes to the immunogenicity and to the exposure of epitopes that are conserved in pandemic variants, such as Omicron. Antibody titers against both RBDs were lower in participants with chronic diseases and in multiparous.</p></div><div><h3>Conclusions</h3><p>This is the first report of simultaneous detection of antibody titers, against the Wuhan-Hu-1 RBD and OmicronBA.5 RBD, in breast milk from puerperal women vaccinated with 3 doses a COVID-19 protein subunit vaccine. There is a tendency to decrease the antibody response after vaccination, due to chronic diseases and multiparity.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.06.003
{"title":"Un sistema inmune en guardia frente al neumococo","authors":"","doi":"10.1016/j.vacun.2024.06.003","DOIUrl":"10.1016/j.vacun.2024.06.003","url":null,"abstract":"<div><p>Pneumococcus is a common colonizer of the human nasopharynx. However, it can also cause human diseases such as otitis or pneumonia, which may progress into invasive forms such as bacteremic pneumonia, meningitis or sepsis. This bacterium reaches and establishes itself in the nasopharynx through different mechanisms, which include evasion of the host immune system. Moreover, certain factors such as the coinfection with viruses favor colonization, as well as the ability of pneumococcus to cause diseases. Our immune system responds to pneumococcal colonization and infection through the innate and adaptive responses, which can be stimulated by pneumococcal vaccines. In the following article, we will briefly review the mechanisms of pneumococcal infection and how our immune system responds to it; as well as the immune response generated after vaccination and its impact on the prevention of pneumococcal disease.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1576988724000475/pdfft?md5=60138af1b6455603d81f759a47fe5840&pid=1-s2.0-S1576988724000475-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141691936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2023.09.004
{"title":"Musculoskeletal and neuromuscular dysfunction due to covid-19 infection: A review","authors":"","doi":"10.1016/j.vacun.2023.09.004","DOIUrl":"10.1016/j.vacun.2023.09.004","url":null,"abstract":"<div><p>The emergence of the novel coronavirus-based illness, COVID-19, in late 2019 marked a watershed moment in modern history. Initially identified in Wuhan, China, this viral epidemic swiftly transformed into a global pandemic, affecting worldwide. The World Health Organization (WHO) officially labeled the virus as “Severe Acute Respiratory Syndrome Coronavirus 2” (SARS-CoV-2) and the ensuing disease as Coronavirus Disease 2019 (COVID-19) on February 11, 2020. The spectrum of effects induced by COVID-19 encompasses a diverse array of conditions, ranging from sensory disturbances like anosmia and ageusia to more intricate manifestations, including headaches and, alarmingly, multiorgan failure and neuromuscular dysfunction, and even deaths were reported. COVID-19 triggers a vigorous inflammatory response characterized by the overproduction of pro-inflammatory cytokines. “Cytokine storm” significantly underwrites the worsening of the condition of patients, resulting in abnormalities such as ARDS. The major reason behind mortality from COVID-19 is respiratory failure instigated by ARDS. Throughout the early respiratory contamination, SARS-CoV-2 was hypothesized to target type-II pneumocytes lining the respiratory passage that specifically expressed TMPRSS2 and ACE2 receptors. The extra-pulmonary consequences of COVID-19 have been linked to the occurrence of these receptors in the skeletomuscular and brain tissues. As a result, it is condemning to comprehend the unique pathophysiological mechanisms behind the virus's manner of invasion in the tissues and also the disease's consequences. In this article, we focus on the complications caused by COVID-19 on musculoskeletal and neural tissues, the route of invasion, and the future perspective of dealing with the receptors whose expression leads to COVID-19 infection.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135762033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.02.001
{"title":"Post COVID-19 era: Re-emergence of known and future (X) viral pathogens","authors":"","doi":"10.1016/j.vacun.2024.02.001","DOIUrl":"10.1016/j.vacun.2024.02.001","url":null,"abstract":"<div><p>The world has successfully overcome the menace of Coronavirus disease-19 (COVID-19) pandemic waves, nature has unleashed a new curveball in the years 2022 and 2023 with other highly infectious viral diseases. Understanding the origin and different transmission routes, evolution, the mechanism of their emergence, immune evasion, and vaccine research while dealing with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has advanced our scientific knowledge and public health infrastructure to address unknown future viral pathogens already underway. The current review briefly discussed the worldwide pandemics of Monkeypox (Mpox) and polio viral infection along with the origin theories of other global viral outbreaks post-COVID-19 era in 2022 and 2023 like Ebola, unexplained hepatitis in pediatric children, avian influenza, and Langya virus. The role of climate, biodiversity, zoonotic transmission, and trajectory of these viral infections. It also highlights the containment, preventive, and treatment strategies that are being developed.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140278919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.06.006
{"title":"Volviendo a las vacunas trivalentes frente a la gripe humana","authors":"","doi":"10.1016/j.vacun.2024.06.006","DOIUrl":"10.1016/j.vacun.2024.06.006","url":null,"abstract":"","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141697918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.04.003
{"title":"Immunoinformatics strategy for designing a multi-epitope chimeric vaccine to combat Neisseria gonorrhoeae","authors":"","doi":"10.1016/j.vacun.2024.04.003","DOIUrl":"10.1016/j.vacun.2024.04.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The increasing prevalence of <em>Neisseria gonorrhoeae</em> has become a significant global concern. Consequently, it is of utmost importance to explore prophylactic approaches to combat the anti-microbial resistance in <em>N. gonorrhoeae</em>.</p></div><div><h3>Objective</h3><p>The present study aims to design a multi-epitopic vaccine construct using immunoinformatics and pan-genomic methodology.</p></div><div><h3>Methods</h3><p>The initial phase involves retrieving and re-annotating the 133 complete genome sets of <em>N. gonorrhoeae</em>. Subsequently, a pan-genome analysis was conducted to identify the core genes, followed by gene mapping. Non-homologous outer-membrane proteins were filtered out and analyzed using various epitope prediction algorithms targeting major histocompatibility complex (MHC-I, MHC-II), and B cells. The optimal epitopes were selected based on immunogenicity, antigenicity, toxicity, and solubility. Then, the vaccine constructs were designed using different combinations of linkers, Histidine (His) tags, adjuvants, and the finalized epitopes.</p></div><div><h3>Results</h3><p>The vaccine construct, V13 was screened as the most suitable candidate based on its physiochemical and antigenicity properties. Computational techniques assessed the efficacy of V13 against different immune receptors supported by immune simulation, indicating its safety for inducing immune responses against <em>N. gonorrhoeae.</em></p></div><div><h3>Conclusion</h3><p>The chimeric multi-epitopic vaccine V13 construct can potentially trigger a diverse array of protective immune responses and serve as a promising starting point for future experimental investigations.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141132964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
VacunasPub Date : 2024-07-01DOI: 10.1016/j.vacun.2024.03.002
{"title":"COVID-19 vaccine rumour and resistance in Indonesia: Analysing vaccine hesitancy and cultural myths circulated on online platforms","authors":"","doi":"10.1016/j.vacun.2024.03.002","DOIUrl":"10.1016/j.vacun.2024.03.002","url":null,"abstract":"<div><h3>Background</h3><p>Rumours and misinformation about the COVID-19 vaccine have been massively circulated on social media platforms, ranging from misleading information, hoaxes, and conspiracy theories to exaggerating stories mixed with the circulation of cultural myths regarding the vaccine.</p></div><div><h3>Methods</h3><p>This study examines the contents of social media platforms such as Twitter, YouTube, TikTok, and WhatsApp posts, also sourced from other Indonesian online portal news and mainstream media websites.</p></div><div><h3>Results</h3><p>This research identifies quantitatively several rumours, misleading information, conspiracy theories, and other misinformation, resistance, and rejection toward issues related to the COVID-19 vaccine from March to April 2021. We then combine it with an analysis of the narratives of vaccine resistance and cultural myths that have made people hesitate or apathetic in participating in national vaccine programs by the Indonesian government.</p></div><div><h3>Conclusion</h3><p>Sourced from the content analysis of this study, we categorised some themes such as vaccine development, availability, access, morbidity, mortality, harmful excesses, safety, and efficacy, both contained and presented in short narratives, visual graphics, memes, and cartoons. This study suggests that these rumours, misleading stories, and myths, may result in the Indonesian public's vaccine resistance and hesitancy, especially since May the Indonesian government stopped distributing the Astra Zeneca vaccines and the controversial issue regarding the availability of ‘Vaccine Nusantara’ (term as ‘Archipelago Vaccine’). This situation may influence the public's attitude to distrust the government and be distracted by misinformation about the vaccination program. Moreover, we see that cultural beliefs and religious stances have made complicated the hesitancy and resistance of the public against the COVID-19 vaccine.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}